Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Suzhou City, China Clinical Trials

A listing of Suzhou City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

The patients will receive infusion of CART cells targeting CD19 and CD22 to confirm the safety and efficacy of CD19/CD22 CART Cells in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

Phase

0.0 miles

Learn More »

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

This is an open-label, single-centre, randomised study, looking at a series of 40 patients up to the age of 75 with newly diagnosed Waldenstrom's macroglobulinemia (WM) not previously treated. Patients will receive RCD or PCD combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try ...

Phase

0.05 miles

Learn More »

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

Adults ages 18-75 with high risk Multiple Myelomas (not achieved VGPR before stem cell mobilization or R-ISS III stage or with extramedullary infiltration or with del(17p), t(4;14), t(14;16)). Design Participants may be screened with:Medical historyPhysical examBlood and urine testsHeart testsBone marrow sampleMultiple scans and X-rays. Participants will have apheresis. Blood ...

Phase

0.05 miles

Learn More »

Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ] Secondary Outcome Measures: The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days ] The area under the plasma concentration-time curve from 0 to inf (infinite) time (AUC0-); ...

Phase

3.13 miles

Learn More »

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Phase

9.68 miles

Learn More »

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Phase

9.68 miles

Learn More »

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Phase

9.68 miles

Learn More »

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant. In addition, some patients who enroll to other CD19-CAR-T cell therapy trials might ...

Phase

9.68 miles

Learn More »

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

PRIMARY OBJECTIVES: Determine the safety and feasibility of the chimeric antigen receptor NK92 cells transduced with the anti-CD33 vector (referred to as anti-CD33 CAR-NK cells). SECONDARY OBJECTIVES: I. For patients with detectable disease, measure anti-leukemia response due to anti-CD33 CAR-NK cell infusions. II. For patients with stored or accessible leukemia ...

Phase

9.68 miles

Learn More »

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.

Phase

9.68 miles

Learn More »